<DOC>
	<DOC>NCT02697773</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the efficacy of a titration arm of tanezumab in which treatment is started at a lower dose (2.5 mg) and increased to a higher dose (5 mg) at Week 8, compared to giving 2 doses of tanezumab 2.5 mg or 2 doses of placebo. The study also evaluates the safety of the treatment regimens.</brief_summary>
	<brief_title>Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Osteoarthritis, Hip</mesh_term>
	<criteria>Diagnosis of Osteoarthritis of the knee or hip confirmed by Xray Documented history that subject tried the following medications and had insufficient pain relief or is cannot take or tolerate them: acetaminophen, NSAIDs and either tramadol or opioids Meet the protocol requirements for pain at screening and pain, physical function and patient global assessment of osteoarthritis at baseline Willing to discontinue all pain medications except study medication and rescue medication during the course of the study and use those as directed per protocol Women able to have children must agree to use 2 forms of contraception during the study Body Mass Index (BMI) greater than 39 History of diseases other than osteoarthritis in a shoulder, hip or knee (example, rheumatoid arthritis, gout, joint infections, osteonecrosis) Patients with xray showing joint conditions such as osteonecrosis (dead bone) or certain types of fractures Patients who have had significant trauma or surgery to a knee, hip or shoulder within the previous year Planned surgical procedure during the study Patients who are largely or wholly incapacitated (example bedridden or confined to a wheelchair, permitting little or no selfcare) Patients who would be unwilling or unable to undergo joint replacement surgery if one eventually became necessary Patients with significant conditions other than osteoarthritis that could interfere with assessment of pain in the joints (example fibromyalgia, lupus erythematosus) Patients with significant heart, neurological or psychiatric diseases Patients who had cancer other than certain skin cancers within the past 5 years Patients with alcohol, analgesic (pain medications) or drug abuse within the past 2 years Women who are pregnant, breastfeeding or intending to become pregnant or breastfeed during the course of the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>osteoarthritis of the knee</keyword>
	<keyword>osteoarthritis of the hip</keyword>
	<keyword>nerve growth factor inhibitor</keyword>
	<keyword>tanezumab</keyword>
</DOC>